As of 2026, Cerebrolysin is not FDA-approved for any indication in the United States
GHK-Cu, a copper-binding peptide with substantial evidence in tissue repair and anti-inflammatory pathways, surfaces in dermatology practices, high-end skincare consultations, and aesthetic medicine contexts with increasing frequency
The result is fewer side effects than the other GLP-1 agonists, along with more weight loss and better insulin control, Skelley notes
Once treatment stops, regain is common
Weston has completed additional training in obesity medicine at the Cleveland Clinic and continues to expand her knowledge by seeking out the most sustainable weight loss methods available
Tackling Adherence Challenges One GLP-1RA at a Time T2DM management has shifted from a one size fits all approach to a more holistic, patient-centred approach that aligns goals of management, such as glycaemic targets and risk factor control (e.g